ESMO open

01 14 October 2026

DOI 10.1016/j.esmoop.2026.108601

Structured physical activity in high-risk stage II and stage III colon cancer: tertiary prevention of colorectal cancer recurrence or primary prevention in a population at high risk of secondary cancers?

Open DOI

R. Moretto, V. Conca, E. Blondeaux et al.

02 13 October 2026

DOI 10.1016/j.esmoop.2026.108584

A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas

Open DOI

W.N. William, L. Feng, M.S. Kies et al.

03 13 October 2026

DOI 10.1016/j.esmoop.2026.108596

“Our patients deserve better”—roadblocks to optimal care in biliary malignancies

Open DOI

A. Lamarca, I. Macias, M.I. Crespo Cruz et al.

04 9 October 2026

DOI 10.1016/j.esmoop.2026.108578

Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial

Open DOI

Y. Nakamura, T. Esaki, T. Nishina et al.

05 9 October 2026

DOI 10.1016/j.esmoop.2026.108590

Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Open DOI

T. Macarulla, R. Pazo Cid, M.S. Womack et al.

06 9 October 2026

DOI 10.1016/j.esmoop.2026.108598

The cost of intensification in high-risk non–muscle-invasive bladder cancer

Open DOI

M. Zugman, I. Kirche Duarte, W. Baccaglini

07 9 October 2026

DOI 10.1016/j.esmoop.2026.108587

A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma

Open DOI

B.I. Rini, T. Powles, P. Tomczak et al.

08 9 October 2026

DOI 10.1016/j.esmoop.2026.108366

First-line toripalimab in combination with platinum-doublet chemotherapy for advanced B3 thymoma and thymic carcinoma: an open-label prospective phase Ⅱ trial

Open DOI

K. Zhu, H. Zhu, H. Shi et al.

09 7 October 2026

DOI 10.1016/j.esmoop.2026.108586

Response to Letter to the Editor: “NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial”

Open DOI

T. Kahl, S.D. Eisenring, G. Liposits

10 1 October 2026

DOI 10.1016/j.esmoop.2026.108552

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

Open DOI

R. Kanesvaran, V. Gruenwald, A. Wong et al.